Showing results (1-10 of 345) with videos related to
Sort By:
Pageof 35
British Journal of Clinical Pharmacology|August 29, 2013
Genetics of platelet inhibitor treatmentDietmar Trenk, Willibald HochholzerCurrent Atherosclerosis Reports|December 18, 2012
Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?Willibald Hochholzer, Robert P GiuglianoDeutsche Medizinische Wochenschrift (1946)|June 3, 2016
[The new 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation]Willibald Hochholzer, Franz-Josef NeumannCirculation|May 25, 2011
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38)Willibald Hochholzer, Stephen D Wiviott, Elliott M Antman, et al.Therapeutic Advances in Cardiovascular Disease|April 20, 2010
Lipid lowering goals: back to nature?Willibald Hochholzer, Robert P GiuglianoCardiology Clinics|October 22, 2008
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?Stephen D WiviottThrombosis and Haemostasis|March 25, 2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 TrialEdward T Carreras, Willibald Hochholzer, Andrew L Frelinger, et al.The American Journal of Cardiology|November 14, 2006
Clopidogrel response variability, resistance, or both?Stephen D WiviottAmerican Heart Journal|October 12, 2010
Novel biomarkers in cardiovascular disease: update 2010Willibald Hochholzer, David A Morrow, Robert P GiuglianoTherapeutic Advances in Cardiovascular Disease|September 7, 2011
The facts behind niacinWillibald Hochholzer, David D Berg, Robert P GiuglianoPageof 35